For early-stage biotech companies, the road from discovery to market is fraught with challenges, and in this environment, strategic partnerships with CROs have become a cornerstone of clinical success.
PFAS restrictions are tightening, but a full ban could disrupt critical industries lacking alternatives, such as pharmaceutical manufacturing. Learn where PFAS use remains indispensable.
These trials present unique logistical hurdles. Success requires a meticulous operational framework, strategic site specialization, and a patient-centric design for smooth execution.
Empower your teams to move beyond static reports by leveraging R Shiny to transform data into interactive, real-time insights that drive smarter, faster decisions.
Successful delivery of a bispecific antibody therapeutic to patients necessitates a manufacturing strategy that can accommodate the unique size, structure, and complexity of these molecules to ensure quality.
A $771 million expansion will bring new biologics and small molecule manufacturing capabilities and create hundreds of jobs. Learn how this investment positions the Research Triangle for future growth.
Recruiting the right patients into a clinical trial is only half the battle. To combat attrition, sponsors must also institute measures that ensure patients remain comfortable and confident throughout the trial.
Unlock the potential of antibody-drug conjugates (ADCs) by exploring our novel payloads, designed for easy access and evaluation, to accelerate your ADC drug development with proven efficacy and safety.
